SGN-00101 (HspE7) [verpasep caltespen] immunotherapy of CIN (cervical intraepithelial neoplasia) III
Phase of Trial: Phase II
Latest Information Update: 25 May 2018
At a glance
- Drugs Verpasep caltespen (Primary)
- Indications Cervical cancer; Cervical intraepithelial neoplasia; Human papillomavirus infections
- Focus Adverse reactions; Therapeutic Use
- 06 Mar 2007 Results have been reported.
- 06 Mar 2007 Status change from recruiting to completed
- 20 Nov 2005 New trial record.